Literature DB >> 35720233

Prognostic factors for in-transit metastasis in patients with malignant melanoma.

Vlad Alexandru Gâta1,2, Andrei Roman3, Maximilian Muntean1,2, Dragoş Ştefan Morariu2, Cătălin Ioan Vlad1,2, Eduard Alexandru Bonci1,2, Alexandru Irimie2,4, Patriciu Achimaş-Cadariu1,2.   

Abstract

Background and aims: Malignant melanoma represents an aggressive and unpredictable malignancy, with high locoregional recurrence rates, regardless of tumor stage and therapeutic management. This study aims to identify the main histopathological prognostic factors involved in the development of in-transit metastasis in patients with malignant melanoma.
Methods: The study includes only patients that were diagnosed with malignant melanoma and with histologically confirmed in-transit metastasis who were treated in a comprehensive cancer center between 2010-2021. Histopathological parameters were investigated, univariate and multivariate analysis was performed.
Results: A total of 26 patients were included in the analysis. On univariate and multivariate analysis, only primary cutaneous melanomas located on the thorax correlated with the risk of developing in-transit metastasis, whereas clinicopathological factors such as an increased Breslow thickness and Clark level, the presence of ulceration, positive lymph nodes, a non-brisk TIL density, a high mitotic rate, a nodular subtype, and age >50 years may represent risk factors, even though we could not find any correlations. Conclusions: Primary cutaneous melanomas that arise on the thorax present a high risk for the occurrence of locoregional disease, whereas other clinicopathological characteristics could not be used to predict local recurrence. However, prospective and more extensive cohort studies are needed in order to validate these important prognostic factors.

Entities:  

Keywords:  in-transit metastasis; malignant melanoma; prognosis; risk factors; tumor-infiltrating lymphocytes

Year:  2022        PMID: 35720233      PMCID: PMC9177086          DOI: 10.15386/mpr-2173

Source DB:  PubMed          Journal:  Med Pharm Rep        ISSN: 2602-0807


  37 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Is there increased risk of local and in-transit recurrence following sentinel lymph node biopsy?

Authors:  Sonja Cerovac; Syed A Mashhadi; Andrew M Williams; Rosemary A Allan; Paul R W Stanley; Barry W E M Powell
Journal:  J Plast Reconstr Aesthet Surg       Date:  2006-02-03       Impact factor: 2.740

3.  In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy.

Authors:  Georgia Beasley; Douglas Tyler
Journal:  Ann Surg Oncol       Date:  2014-09-30       Impact factor: 5.344

4.  Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.

Authors:  Sandra L Wong; Mark B Faries; Erin B Kennedy; Sanjiv S Agarwala; Timothy J Akhurst; Charlotte Ariyan; Charles M Balch; Barry S Berman; Alistair Cochran; Keith A Delman; Mark Gorman; John M Kirkwood; Marc D Moncrieff; Jonathan S Zager; Gary H Lyman
Journal:  Ann Surg Oncol       Date:  2017-12-13       Impact factor: 5.344

5.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.

Authors:  Farhad Azimi; Richard A Scolyer; Pavlina Rumcheva; Marc Moncrieff; Rajmohan Murali; Stanley W McCarthy; Robyn P Saw; John F Thompson
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

6.  Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Daniel G Coit; John A Thompson; Mark R Albertini; Christopher Barker; William E Carson; Carlo Contreras; Gregory A Daniels; Dominick DiMaio; Ryan C Fields; Martin D Fleming; Morganna Freeman; Anjela Galan; Brian Gastman; Valerie Guild; Douglas Johnson; Richard W Joseph; Julie R Lange; Sameer Nath; Anthony J Olszanski; Patrick Ott; Aparna Priyanath Gupta; Merrick I Ross; April K Salama; Joseph Skitzki; Jeffrey Sosman; Susan M Swetter; Kenneth K Tanabe; Evan Wuthrick; Nicole R McMillian; Anita M Engh
Journal:  J Natl Compr Canc Netw       Date:  2019-04-01       Impact factor: 11.908

7.  Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.

Authors:  Lutz Kretschmer; Iris Beckmann; Kai-Martin Thoms; Christina Mitteldorf; Hans Peter Bertsch; Christine Neumann
Journal:  Ann Surg Oncol       Date:  2006-07-24       Impact factor: 5.344

8.  Primary excision margins, sentinel lymph node biopsy, and completion lymph node dissection in cutaneous melanoma: a clinical practice guideline.

Authors:  F C Wright; L H Souter; S Kellett; A Easson; C Murray; J Toye; D McCready; C Nessim; D Ghazarian; N J Look Hong; S Johnson; D P Goldstein; T Petrella
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

Review 9.  Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.

Authors:  Nayoung Lee; Labib R Zakka; Martin C Mihm; Tobias Schatton
Journal:  Pathology       Date:  2016-01-16       Impact factor: 5.306

10.  The prognostic significance of ulceration of cutaneous melanoma.

Authors:  C M Balch; J A Wilkerson; T M Murad; S J Soong; A L Ingalls; W A Maddox
Journal:  Cancer       Date:  1980-06-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.